Elypta's Urine Biomarker Predicts Five-Year Cancer Risk in Adults

STOCKHOLM, Nov. 11, 2026 /CourierPR/ -- Elypta, a cancer risk-stratification company, has announced the results of a study that demonstrates the potential of a urine-based biomarker to predict five-year cancer risk in healthy adults. The study, published in the peer-reviewed journal Cancer Epidemiology, Biomarkers & Prevention, included 5,436 adults and was sponsored by Elypta.

The research focused on a urine profile of three glycosaminoglycan disacharrides (GAGs), which are sugar chains involved in cancer-related processes. The study found that a GAG profile, known as the GAGome score, could place an estimated 13-23% of participants in a pre-specified high-risk group. This group accounted for 54% of cancers diagnosed within five years and 54% of in situ carcinomas. In contrast, only about 17% of people who stayed cancer-free fell into this high-risk category.

The GAGome score performed at least as well in adults under 50 and was particularly effective for cancers without population screening, such as pancreatic, kidney, brain cancer, and lymphoma. The study used 24-hour urine samples from a Dutch Lifelines cohort of 124,436 adults. Researchers analyzed all 827 people later diagnosed with cancer and a random sample of 4,609 who were not. Three chondroitin sulfate disaccharides were measured by mass spectrometry. The retrospective study was pre-registered (NCT05235009).

While the GAGome score shows promise, it requires independent prospective validation before any clinical use. Elypta offers the MIRAM® GAGome Kit for quantification of urine CS disaccharides (FRUOU-CS) by UHPLC-MS/MS for Research Use Only. Not for use in diagnostic procedures.